Teligene
↗Suzhou, China (US subsidiary: Thousand Oaks, California)
Suzhou Teligene is a privately-held pharmaceutical biotech company founded in 2011 by Dr. Zhang Dawei, a former chief scientist at Amgen. The company specializes in the research, development, and industrialization of innovative small-molecule targeted drugs, with primary focus on oncology therapeutics for unmet medical needs. Teligene operates in China (headquarters in Suzhou Bio-Nano Park) and maintains a US subsidiary, Teligene US LLC, based in Thousand Oaks, California. The company has developed a comprehensive pipeline of drug candidates at various clinical and preclinical stages, with approximately 22 active clinical trials and a focus on developing novel PI3K inhibitors and other kinase inhibitors for cancer treatment. Teligene combines computational drug screening with traditional medicinal chemistry approaches to identify novel small-molecule candidates with potential advantages over existing therapeutics.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2011
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
Total Raised:$123M
Investors:GTJA Investment Group, Alan Asset Management, China Reform Holdings Corporation, CICC Jia Cheng Investment Management Company, Global X, Kangcheng Capital
PIPELINE
Stage:Preclinical to Phase II
Lead Drug Stage:Phase I/II
Modalities:Small molecule, PI3K inhibitors, Protein kinase inhibitors, ROS1 inhibitors
Active Trials:22
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Teligene US LLC (Thousand Oaks, California)
COMPETITION
Position:Emerging
Competitors:Verastem (RAS/MAPK inhibitors), Karyopharm Therapeutics (nuclear export inhibitors), Tango Therapeutics (small molecule oncology), Orionis Biosciences (Roche/Genentech partnership), Exelixis (multi-target small molecule programs)
LEADERSHIP
Key Executives:
Dr. Zhang Dawei - Founder
Scientific Founders:Dr. Zhang Dawei
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Teligene and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Teligene. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.